Skip to content
Screener

Precigen PGEN Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.61B-241%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$92.7M+91.5%
Gilead Sciences logo
Gilead SciencesGILD
-$10.35B-389%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$29.59M-579%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$35.35M-372%
Regenxbio logo
RegenxbioRGNX
$65.93M+147%

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$2.47B+358%
Enterprise value$2.56B+382%
P/S93.2×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Precigen’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356090-26-000017
(Amounts in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Purchases of investments$(33,874)$(10,408)
Sales and maturities of investments55,0994,573
Purchases of property, plant and equipment(258)(622)
Net cash provided by (used in) investing activities20,967(6,457)
Cash flows from financing activities
Payment of issuance cost related to 2024 public offering of shares(355)
Payments to taxing authorities in connection with shares directly withheld from employees(146)(474)
Proceeds from stock option exercises255150

Item 1. Condensed Consolidated Financial Statements

FAQ

What is Precigen's investing cash flow?
Precigen (PGEN) reported investing cash flow of $20.97M in Q1 2026.
How has Precigen's investing cash flow changed year-over-year?
Precigen's investing cash flow increased by 424.7% year-over-year, from -$6.46M to $20.97M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Precigen's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude